-
1
-
-
0029887202
-
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
-
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496.
-
(1996)
Dermatol Clin
, vol.14
, pp. 485-496
-
-
Koo, J.1
-
3
-
-
1842555395
-
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
-
Stem RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
-
(2004)
J Investig Dermatol Symp Proc
, vol.9
, pp. 136-139
-
-
Stem, R.S.1
Nijsten, T.2
Feldman, S.R.3
-
5
-
-
14244258610
-
Psoriasis pathophysiology: Current concepts of pathogenesis
-
Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(suppl 2):ii30-ii36.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 2
-
-
Krueger, J.G.1
Bowcock, A.2
-
6
-
-
0032872277
-
Psoriasis causes as much disability as other major medical diseases
-
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401-407.
-
(1999)
J Am Acad Dermatol
, vol.41
, Issue.3 PART 1
, pp. 401-407
-
-
Rapp, S.R.1
Feldman, S.R.2
Exum, M.L.3
-
7
-
-
77949316248
-
-
The Lewin Group Inc, Prepared for the Society for Investigative Dermatology and the American Academy of Dermatology Association, Accessed October 14, 2008
-
The Lewin Group Inc. The Burden of Skin Diseases 2004. Prepared for the Society for Investigative Dermatology and the American Academy of Dermatology Association. http://www.sidnet.org/pdfs/Burden%20of%20Skin%20Diseases%202004. pdf. Accessed October 14, 2008.
-
(2004)
The Burden of Skin Diseases
-
-
-
8
-
-
0036621075
-
The direct cost of care for psoriasis and psoriatic arthritis in the United States
-
Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
-
(2002)
J Am Acad Dermatol
, vol.46
, pp. 850-860
-
-
Javitz, H.S.1
Ward, M.M.2
Farber, E.3
-
9
-
-
33646441017
-
The cost of psoriasis
-
5suppl:10- 13
-
Crown WH. The cost of psoriasis. Manag Care. 2003;12(5suppl):10- 13.
-
(2003)
Manag Care
, pp. 12
-
-
Crown, W.H.1
-
10
-
-
77949322158
-
-
Research Pipeline. Treatments in Development for Psoriasis and/or Psoriatic Arthritis, Accessed October 14, 2008
-
National Psoriasis Foundation. National Psoriasis Foundation 2008 Research Pipeline. Treatments in Development for Psoriasis and/or Psoriatic Arthritis, http://www.psoriasis.org/files/pdfs/research/pipeline-03-08ltr.pdf. Accessed October 14, 2008.
-
(2008)
-
-
-
12
-
-
41849102049
-
A strategic plan for integrating cost-effectiveness analysis into the US healthcare system
-
Neumann PJ, Palmer JA, Daniels N, et al. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care. 2008;14:185-188.
-
(2008)
Am J Manag Care
, vol.14
, pp. 185-188
-
-
Neumann, P.J.1
Palmer, J.A.2
Daniels, N.3
-
13
-
-
85136365594
-
-
Justice AC, Cho MK, Winker MA, et al. Does masking author identity improve peer review quality? A randomized controlled trial. PEER Investigators [published correction appears in JAMA. 1998;80:968. JAMA. 1998;280:240-242.
-
Justice AC, Cho MK, Winker MA, et al. Does masking author identity improve peer review quality? A randomized controlled trial. PEER Investigators [published correction appears in JAMA. 1998;80:968). JAMA. 1998;280:240-242.
-
-
-
-
14
-
-
0038120138
-
Appraising systematic reviews and meta-analyses
-
Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol. 2003;139:795-798.
-
(2003)
Arch Dermatol
, vol.139
, pp. 795-798
-
-
Bigby, M.1
Williams, H.2
-
15
-
-
0041632271
-
Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors
-
Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003;49(2 suppl):S39-S43.
-
(2003)
J Am Acad Dermatol
, vol.49
, Issue.2 SUPPL.
-
-
Menter, M.A.1
Krueger, G.C.2
Feldman, S.R.3
Weinstein, G.D.4
-
16
-
-
0141955042
-
Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis
-
Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158-165.
-
(2003)
J Dermatolog Treat
, vol.14
, pp. 158-165
-
-
Weisman, S.1
Pollack, C.R.2
Gottschalk, R.W.3
-
17
-
-
0018099294
-
Severe psoriasis - oral therapy with a new retinoid
-
Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
-
(1978)
Dermatologica
, vol.157
, Issue.4
, pp. 238-244
-
-
Fredriksson, T.1
Pettersson, U.2
-
18
-
-
2542445474
-
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
-
Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-866.
-
(2004)
J Am Acad Dermatol
, vol.50
, pp. 859-866
-
-
Carlin, C.S.1
Feldman, S.R.2
Krueger, J.G.3
-
19
-
-
14244250511
-
Psoriasis assessment tools in clinical trials
-
Feldman SR, Kreuger GC. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl 2):ii65-ii68.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 2
-
-
Feldman, S.R.1
Kreuger, G.C.2
-
20
-
-
23944523103
-
A cost comparison of treatments for moderate to severe psoriasis
-
HankinCS, Feldman SR, Szczotka A, etal. A cost comparison of treatments for moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200-214.
-
(2005)
Drug Benefit Trends
, vol.17
, pp. 200-214
-
-
Hankin, C.S.1
Feldman, S.R.2
Szczotka, A.3
-
21
-
-
37349061697
-
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period
-
Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125-135.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 125-135
-
-
Nelson, A.A.1
Pearce, D.J.2
Fleischer Jr, A.B.3
-
22
-
-
33144473657
-
Cost-effectiveness of moderate-to-severe psoriasis treatment
-
Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7:157-167.
-
(2006)
Expert Opin Pharmacother
, vol.7
, pp. 157-167
-
-
Miller, D.W.1
Feldman, S.R.2
-
23
-
-
77949329781
-
-
Amevive package insert, Cambridge, MA: Biogen, Inc; 2003
-
Amevive (package insert]. Cambridge, MA: Biogen, Inc; 2003.
-
-
-
-
24
-
-
77949319469
-
-
Raptiva [package insert, South San Francisco, CA: Genentech, Inc; 2005
-
Raptiva [package insert]. South San Francisco, CA: Genentech, Inc; 2005.
-
-
-
-
25
-
-
77949329231
-
-
Enbrel [package insert, Thousand Oaks, CA: Immunex Corporation; 2009
-
Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2009.
-
-
-
-
26
-
-
77949333200
-
-
Humira [package insert, North Chicago, IL: Abbott Laboratories; 2008
-
Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2008.
-
-
-
-
27
-
-
69749085182
-
Long-term efficacy of biologics in the treatment of psoriasis: What do we really know?
-
Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431-440.
-
(2009)
Dermatol Ther
, vol.22
, pp. 431-440
-
-
Alwawi, E.A.1
Krulig, E.2
Gordon, K.B.3
-
30
-
-
77949332857
-
Patterns of care in the pharmacologic treatment of moderate-to-severe psoriasis
-
Poster presented at the May 16-20, Orlando, FL
-
Hankin CS, Lebwohl M, Knispel J, et al. Patterns of care in the pharmacologic treatment of moderate-to-severe psoriasis. Poster presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Health Outcomes Research; May 16-20,2009; Orlando, FL.
-
(2009)
14th Annual International Meeting of the International Society for Pharmacoeconomics and Health Outcomes Research
-
-
Hankin, C.S.1
Lebwohl, M.2
Knispel, J.3
-
31
-
-
78650106911
-
-
McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports; no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
-
McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports; no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
-
-
-
-
32
-
-
0036884653
-
Management of guttate and generalized psoriasis vulgaris: Prospective randomized study
-
Caca-Biljanovska NG, V'Ickova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J. 2002;43:707-712.
-
(2002)
Croat Med J
, vol.43
, pp. 707-712
-
-
Caca-Biljanovska, N.G.1
V'Ickova-Laskoska, M.T.2
-
33
-
-
0025877405
-
Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone
-
Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24:591-594.
-
(1991)
J Am Acad Dermatol
, vol.24
, pp. 591-594
-
-
Lowe, N.J.1
Prystowsky, J.H.2
Bourget, T.3
-
34
-
-
0027495835
-
Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study
-
Gollnick H, Zaun H, Ruzicka T, et al. Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study. Eur J Dermatol. 1993;3:442-446.
-
(1993)
Eur J Dermatol
, vol.3
, pp. 442-446
-
-
Gollnick, H.1
Zaun, H.2
Ruzicka, T.3
-
35
-
-
0034786155
-
Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial
-
Reitamo S, Spuls P, Sassolas B, et al; Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001;145:438-445.
-
(2001)
Br J Dermatol
, vol.145
, pp. 438-445
-
-
Reitamo, S.1
Spuls, P.2
Sassolas, B.3
-
36
-
-
0026013163
-
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial
-
Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
-
(1991)
N Engl J Med
, vol.324
, pp. 277-284
-
-
Ellis, C.N.1
Fradin, M.S.2
Messana, J.M.3
-
37
-
-
0036039938
-
Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis
-
Chládek J, Grim J, Martinková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54:147-156.
-
(2002)
Br J Clin Pharmacol
, vol.54
, pp. 147-156
-
-
Chládek, J.1
Grim, J.2
Martinková, J.3
-
38
-
-
39049143819
-
CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
-
Saurat JH, Stingl G, Dubertret L, et al; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
-
(2008)
Br J Dermatol
, vol.158
, pp. 558-566
-
-
Saurat, J.H.1
Stingl, G.2
Dubertret, L.3
-
39
-
-
33748936662
-
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
-
Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
-
(2006)
J Am Acad Dermatol
, vol.55
, pp. 598-606
-
-
Gordon, K.B.1
Langley, R.G.2
Leonardi, C.3
-
40
-
-
37349003068
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
-
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 106-115
-
-
Menter, A.1
Tyring, S.K.2
Gordon, K.3
-
41
-
-
0038385972
-
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
-
Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
-
(2003)
Arch Dermatol
, vol.139
, pp. 719-727
-
-
Lebwohl, M.1
Christophers, E.2
Langley, R.3
-
42
-
-
0345107256
-
Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
-
Lebwohl M, Tyring SK, Hamilton TK, et al; Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
-
(2003)
N Engl J Med
, vol.349
, pp. 2004-2013
-
-
Lebwohl, M.1
Tyring, S.K.2
Hamilton, T.K.3
-
43
-
-
33745038011
-
CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial
-
Dubertret L, Sterry W, Bos JD, et al; CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-181.
-
(2006)
Br J Dermatol
, vol.155
, pp. 170-181
-
-
Dubertret, L.1
Sterry, W.2
Bos, J.D.3
-
44
-
-
17144388751
-
Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
-
Leonardi CL, Papp KA, Gordon KB, et al; Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 pt 1):425-433.
-
(2005)
J Am Acad Dermatol
, vol.52
, Issue.3 PART 1
, pp. 425-433
-
-
Leonardi, C.L.1
Papp, K.A.2
Gordon, K.B.3
-
45
-
-
12444336904
-
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
-
Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38.
-
(2005)
Arch Dermatol
, vol.141
, pp. 31-38
-
-
Menter, A.1
Gordon, K.2
Carey, W.3
-
46
-
-
0344926414
-
Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis
-
Leonardi CL, Powers JL, Matheson RT, et al; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
-
(2003)
N Engl J Med
, vol.349
, pp. 2014-2022
-
-
Leonardi, C.L.1
Powers, J.L.2
Matheson, R.T.3
-
47
-
-
21644481166
-
Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
-
Papp KA, Tyring S, Lahfa M, et al; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
-
(2005)
Br J Dermatol
, vol.152
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
-
48
-
-
0035832515
-
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised triaL
-
Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised triaL Lancet. 2001;357:1842-1847.
-
(2001)
Lancet
, vol.357
, pp. 1842-1847
-
-
Chaudhari, U.1
Romano, P.2
Mulcahy, L.D.3
-
49
-
-
0033967598
-
Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group
-
Ramsay CA, Schwartz BE, Lowson D, et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000;200:17-24.
-
(2000)
Dermatology
, vol.200
, pp. 17-24
-
-
Ramsay, C.A.1
Schwartz, B.E.2
Lowson, D.3
-
50
-
-
0034745160
-
Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: Results of a comparative study
-
Ring J, Kowalzick L, Christophers E, et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001;144:495-499.
-
(2001)
Br J Dermatol
, vol.144
, pp. 495-499
-
-
Ring, J.1
Kowalzick, L.2
Christophers, E.3
-
51
-
-
0041633617
-
Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial
-
Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149:146-150.
-
(2003)
Br J Dermatol
, vol.149
, pp. 146-150
-
-
Woo, W.K.1
McKenna, K.E.2
-
52
-
-
1842663103
-
A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
-
Torras H, Aliaga A, Lopez-Estebaranz JL, et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat. 2004;15:98-103.
-
(2004)
J Dermatolog Treat
, vol.15
, pp. 98-103
-
-
Torras, H.1
Aliaga, A.2
Lopez-Estebaranz, J.L.3
-
53
-
-
0024312928
-
A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
-
Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989;121:107-112.
-
(1989)
Br J Dermatol
, vol.121
, pp. 107-112
-
-
Lauharanta, J.1
Geiger, J.M.2
-
54
-
-
77949322374
-
-
Soriatane [package insert, Coral Gables, FL: Stiefel Laboratories, Inc; 2007
-
Soriatane [package insert]. Coral Gables, FL: Stiefel Laboratories, Inc; 2007.
-
-
-
-
55
-
-
77949328630
-
-
Neoral [package insert, East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005
-
Neoral [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
-
-
-
-
56
-
-
77949328753
-
-
Trexall [package insert, Pomona, NY: Duramed Pharmaceuticals, Inc; 2005
-
Trexall [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc; 2005.
-
-
-
-
57
-
-
77949328156
-
-
Remicade [package insert, Malvern, PA: Centocor, Inc; 2007
-
Remicade [package insert]. Malvern, PA: Centocor, Inc; 2007.
-
-
-
-
58
-
-
33645442412
-
The art and practice of UVB phototherapy for the treatment of psoriasis
-
Weinstein GD, Gottleib AB, eds, Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker, Inc;
-
Koo J, Bandow G, Feldman SR. The art and practice of UVB phototherapy for the treatment of psoriasis. In: Weinstein GD, Gottleib AB, eds. Therapy of Moderate-to-Severe Psoriasis: Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker, Inc; 2003:53-90.
-
(2003)
Therapy of Moderate-to-Severe Psoriasis
, pp. 53-90
-
-
Koo, J.1
Bandow, G.2
Feldman, S.R.3
-
59
-
-
10844235760
-
Systemic and topical PUVA therapy
-
Weinstein GD, Gottlieb AB, eds, Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker;
-
Morison WL. Systemic and topical PUVA therapy. In: Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis: Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker; 2003:91-114.
-
(2003)
Therapy of Moderate-to-Severe Psoriasis
, pp. 91-114
-
-
Morison, W.L.1
|